STARHEALTH - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.3
| Stock Code | STARHEALTH | Market Cap | 26,625 Cr. | Current Price | 453 ₹ | High / Low | 534 ₹ |
| Stock P/E | 59.7 | Book Value | 127 ₹ | Dividend Yield | 0.00 % | ROCE | 12.0 % |
| ROE | 9.37 % | Face Value | 10.0 ₹ | DMA 50 | 460 ₹ | DMA 200 | 460 ₹ |
| Chg in FII Hold | 0.56 % | Chg in DII Hold | -0.13 % | PAT Qtr | 128 Cr. | PAT Prev Qtr | 54.9 Cr. |
| RSI | 44.9 | MACD | -1.23 | Volume | 12,84,599 | Avg Vol 1Wk | 6,32,373 |
| Low price | 327 ₹ | High price | 534 ₹ | PEG Ratio | 1.59 | Debt to equity | 0.06 |
| 52w Index | 60.6 % | Qtr Profit Var | -40.4 % | EPS | 7.59 ₹ | Industry PE | 32.6 |
📊 Analysis: Star Health (STARHEALTH) trades at expensive valuations (P/E 59.7 vs industry 32.6) despite modest efficiency metrics (ROE 9.37%, ROCE 12.0%). Dividend yield is negligible (0.00%). PEG ratio (1.59) suggests fair growth-adjusted valuation. Quarterly PAT improved (₹54.9 Cr → ₹128 Cr), but profit variation (-40.4%) highlights volatility. Technical indicators (RSI 44.9, MACD -1.23) show weak momentum, with price consolidating near both 50 DMA (₹460) and 200 DMA (₹460). The stock has corrected from its 52-week high (₹534 → ₹453), now trading close to support levels.
💡 Entry Price Zone: Ideal accumulation range is between ₹440–₹460, closer to DMA support levels, offering better risk-reward relative to valuations.
📈 Exit / Holding Strategy: If already holding, maintain a medium-to-long-term horizon (3–5 years). Consider partial profit booking if price revisits ₹510–₹530. Long-term investors should wait for improvement in ROE and earnings consistency before aggressive accumulation.
✅ Positive
- ROCE (12.0%) and ROE (9.37%) show moderate efficiency.
- Quarterly PAT improved (₹54.9 Cr → ₹128 Cr).
- FIIs increased holdings (+0.56%).
- Debt-to-equity ratio is low (0.06), ensuring financial stability.
⚠️ Limitation
- High valuation (P/E 59.7 vs industry 32.6).
- Dividend yield negligible (0.00%).
- Profit variation (-40.4%) highlights earnings volatility.
📉 Company Negative News
- Stock corrected from 52-week high (₹534 → ₹453).
- DIIs reduced holdings (-0.13%).
- Weak technical momentum (RSI below 50, MACD negative).
📈 Company Positive News
- Quarterly PAT more than doubled (₹54.9 Cr → ₹128 Cr).
- FIIs increased stake (+0.56%).
🏦 Industry
- Health insurance sector benefits from rising demand and regulatory support.
- Industry P/E (32.6) indicates moderate valuations compared to STARHEALTH’s premium.
🔎 Conclusion
Star Health is a financially stable company with moderate efficiency metrics and improving profitability, but valuations are stretched and earnings remain volatile. Best suited for medium-to-long-term investors who can accumulate near ₹440–₹460 and hold for 3–5 years, while monitoring profitability trends. Short-term traders may consider profit booking near ₹510–₹530.